← Back to Search

ACT Program for Acute Kidney Injury

N/A
Waitlist Available
Led By Erin Barreto, PharmD, RPh
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days after hospitalization
Awards & highlights

Study Summary

This trial is testing new ways to educate and coordinate care for people who have survived Acute Kidney Injury.

Who is the study for?
This trial is for English-speaking individuals in Olmsted County who have recently been hospitalized with severe stage III Acute Kidney Injury, based on specific lab results. It's not open to those with dementia, enrolled in a Primary Care Transitions Program, expecting dismissal to nursing or hospice care, needing dialysis upon discharge, or recent transplant recipients.Check my eligibility
What is being tested?
The study is testing the 'AKI in Care Transitions (ACT) program', which aims to improve education and coordination of kidney care for patients recovering from severe acute kidney injury after they leave the hospital.See study design
What are the potential side effects?
Since this trial focuses on educational and care coordination interventions rather than medications or medical procedures, traditional side effects are not applicable. However, participants may experience stress or anxiety related to participation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days after hospitalization
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days after hospitalization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of subjects to complete the ACT program

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: AKI in Care Transitions (ACT) GroupExperimental Treatment1 Intervention
Subjects diagnosed with Acute Kidney Injury (AKI) during their hospital stay will participate in the ACT program which provides standardized education and assists with coordination of follow up care after hospital stay.
Group II: Usual Care GroupActive Control1 Intervention
Subjects diagnosed with Acute Kidney Injury (AKI) during their hospital stay will receive standard of care from their inpatient and outpatient care teams.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,205 Previous Clinical Trials
3,766,734 Total Patients Enrolled
11 Trials studying Acute Kidney Injury
5,987 Patients Enrolled for Acute Kidney Injury
Agency for Healthcare Research and Quality (AHRQ)FED
399 Previous Clinical Trials
6,822,298 Total Patients Enrolled
Erin Barreto, PharmD, RPhPrincipal InvestigatorMayo Clinic

Media Library

AKI in Care Transitions (ACT) program Clinical Trial Eligibility Overview. Trial Name: NCT05184894 — N/A
Acute Kidney Injury Research Study Groups: AKI in Care Transitions (ACT) Group, Usual Care Group
Acute Kidney Injury Clinical Trial 2023: AKI in Care Transitions (ACT) program Highlights & Side Effects. Trial Name: NCT05184894 — N/A
AKI in Care Transitions (ACT) program 2023 Treatment Timeline for Medical Study. Trial Name: NCT05184894 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining vacancies in this research endeavor?

"Indeed, the information displayed on clinicaltrials.gov attests to this medical trial's active search for participants. It was posted on 17th January 2022 and updated lastly on 3rd February of that same year. The project necessitates 100 volunteers from a single site."

Answered by AI

How many individuals have opted to partake in this research?

"Affirmative. As evidenced on clinicaltrials.gov, this research is currently recruiting volunteers; it was initially posted on January 17th 2022 and last modified February 3rd 2022. Altogether, the experiment requires 100 participants from one medical centre to take part in the trial."

Answered by AI
~15 spots leftby Apr 2025